La Force & Max’s Big Ride in the parliament of Canada
A memorable day Monday, June 10 was the day that closed the loop of the event of Max’s Big Ride to End Duchenne Muscular Dystrophy. Our two families are living with Duchenne muscular dystrophy. We share the same battle, that of access to treatment. Yesterday was a memorable day because the government has heard us. […]
An international study to learn about your preferences for DMD Treatments
La Force DMD is seeking your participation in a research survey for parents or guardians of sons with Duchenne muscular dystrophy and adult men (18+ years) with Duchenne. This is an international survey about your preferences and priorities for Duchenne treatments. Regulatory agencies such as the EMA and FDA rely on the input of patients, […]
PolarisDMD Welcomes European Sites!
27 global sites currently open for enrollment Clinical trial sites in Europe are now open for enrollment in Bristol and Manchester, England; Munich and Hamburg, Germany; Dublin, Ireland; and Gothenburg, Sweden, with additional sites in Europe expected in the coming weeks. This means that PolarisDMD is now active in 7 countries! The Phase 3 PolarisDMD […]
Clinical Trials Simplified and La Force DMD join forces
Clinical Trials Simplified and La Force DMD join forces to accelerate the development of new therapies for DMD During a conference about rare diseases, Marie-Catherine Du Berger, president of La Force DMD met Carole Abi Farah, Ph.D., General Manager and Co-founder of Simplified Clinical Trials. Clinical trials provide early access to treatments, contribute to medical […]
Without research, there are no new treatments
Duchenne muscular dystrophy (DMD) is a disease that almost exclusively affects boys and whose incidence is 1 in 3,500 – 5,000. It is extremely rare that Duchenne muscular dystrophy (DMD) will affect girls. It is a degenerative disease of the muscles caused by a genetic mutation. The Duchenne muscular dystrophy (DMD) – for which no […]
Translarna™ (ataluren) is the First Therapy Approved in Brazil for DMD
– Ambulatory Duchenne patients who are five years and older with a nonsense mutation can now access a treatment that targets the underlying cause of DMD – PTC Therapeutics, Inc. today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the […]
